<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO>WSJ920228-0162</DOCNO><DOCID>920228-0162.</DOCID><HL>   Who's News:   Genetic Therapy Inc.</HL><DATE>02/28/92</DATE><SO>WALL STREET JOURNAL (J), PAGE B5</SO><CO>   GTII WNEWS</CO><MS>TECHNOLOGY (TEC)</MS><IN>BIOTECHNOLOGY (BTC)MEDICAL andamp; BIOTECHNOLOGY, GENETIC RESEARCH, PROSTHETICS (MTC)</IN><NS>PERSONNEL ANNOUNCEMENTS, PROMOTIONS, APPOINTMENTS (PER)</NS><RE>MARYLAND (MD)NORTH AMERICA (NME)UNITED STATES (US)</RE><LP>   GENETIC THERAPY Inc. (Gaithersburg, Md.) -- Jacques F.Rejeange, 51 years old, was named a director of this humangene therapy research and development firm. Mr. Rejeange ispresident and chief executive of Sandoz PharmaceuticalsCorp., East Hanover, N.J., a unit of Sandoz AG, the Swisspharmaceutical concern. His appointment increases the boardto nine members. Sandoz and Genetic Therapy entered into acollaborative agreement in 1991 that entitled Sandoz to onemember on Genetic's board.</LP><TEXT/></DOC>